Dynamic Technology Lab Private Ltd Increases Holdings in Illumina, Inc. (NASDAQ:ILMN)

Dynamic Technology Lab Private Ltd lifted its stake in Illumina, Inc. (NASDAQ:ILMN) by 110.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,471 shares of the life sciences company’s stock after buying an additional 3,924 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Illumina were worth $998,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of ILMN. Bleakley Financial Group LLC purchased a new stake in shares of Illumina during the fourth quarter valued at approximately $751,000. Zacks Investment Management purchased a new stake in Illumina during the 3rd quarter worth $2,924,000. Van ECK Associates Corp lifted its holdings in Illumina by 17.5% in the 4th quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company’s stock worth $20,347,000 after buying an additional 22,718 shares in the last quarter. Strategic Financial Concepts LLC purchased a new position in Illumina in the 4th quarter valued at about $1,464,000. Finally, Allworth Financial LP grew its stake in shares of Illumina by 720.7% during the fourth quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company’s stock valued at $1,001,000 after acquiring an additional 6,263 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ILMN has been the topic of several recent analyst reports. Piper Sandler boosted their price target on Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Hsbc Global Res lowered Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. Citigroup decreased their price target on shares of Illumina from $130.00 to $90.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. HSBC cut shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target on the stock. in a report on Friday, February 28th. Finally, Morgan Stanley decreased their price objective on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $140.90.

Illumina Stock Down 3.0 %

Shares of Illumina stock opened at $74.16 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. Illumina, Inc. has a 1-year low of $70.64 and a 1-year high of $156.66. The business’s fifty day moving average price is $96.82 and its two-hundred day moving average price is $125.06. The company has a market capitalization of $11.75 billion, a P/E ratio of -9.66, a PEG ratio of 1.60 and a beta of 1.38.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.